2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow vorapaxar: new trials by email Literature Review of vorapaxar trials Research Report on vorapaxar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) Vorapaxar 2.5 mg, Placebo - Atherosclerosis, Ischemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 258 | 2008-07-01 | 2018-09-21 |
| Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736) Vorapaxar, Placebo - Atherosclerosis, Myocardial Ischemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 12944 | 2007-12-01 | 2018-09-21 |
| Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Vorapaxar, Placebo - Atherosclerosis, Ischemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 26449 | 2007-09-01 | 2018-09-21 |
Atherosclerosis (3) · Myocardial Infarction (3) · Ischemia (2) · Stroke (2) · Myocardial Ischemia (1) · Peripheral Arterial Disease (1)
PMID 35224730, PMID 19699853, PMID 19699854, PMID 22077816, PMID 22443427, PMID 22932716, PMID 23396280, PMID 23501976, PMID 24211500, PMID 24402559, PMID 25012288, PMID 25129064, PMID 25465416, PMID 25465417, PMID 25681464, PMID 25792124, PMID 26025218, PMID 26089177, PMID 26338971, PMID 26826179, PMID 26876014, PMID 27151345, PMID 27162212, PMID 27431644, PMID 27440003, PMID 27502866, PMID 27765312, PMID 29910052, PMID 31642690, PMID 32000630, PMID 33884889, PMID 36302586